AMARIN CORP PLC -ADR (AMRN)

US0231112063 - ADR

0.8755  -0.1 (-10.21%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

AMARIN CORP PLC -ADR

NASDAQ:AMRN (5/8/2024, 2:52:04 PM)

0.8755

-0.1 (-10.21%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap351.39M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

AMRN Daily chart

Company Profile

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The firm operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Company Info

AMARIN CORP PLC -ADR

First Floor, Block 3, The Oval,, Shelbourne Road, Ballsbridge

DUBLIN Dublin 2

P: 35316699020

CEO: John F. Thero

Employees: 365

Website: https://amarincorp.com/

AMRN News

News Image2 days ago - Amarin Corporation plcAmarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
News Image2 days ago - Amarin Corporation plcAmarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin’s...

News Image7 days ago - InvestorPlaceAMRN Stock Earnings: Amarin Corp Beats EPS, Misses Revenue for Q1 2024

AMRN stock results show that Amarin Corp beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

News Image7 days ago - The Motley FoolAmarin Plc (AMRN) Q1 2024 Earnings Call Transcript

AMRN earnings call for the period ending March 31, 2024.

News Image7 days ago - Amarin Corporation plcAmarin Reports First Quarter 2024 Business Update and Financial Results
News Image7 days ago - Amarin Corporation plcAmarin Reports First Quarter 2024 Business Update and Financial Results

-- New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 -- -- In Europe, ~35% Revenue...

AMRN Twits

Here you can normally see the latest stock twits on AMRN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example